No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IART Integra Lifesciences
- 27.110
- -0.430-1.56%
Trading May 20 13:45 ET
2.14BMarket Cap53.16P/E (TTM)
27.790High27.064Low180.90KVolume27.420Open27.540Pre Close4.94MTurnover0.27%Turnover Ratio32.27P/E (Static)78.80MShares46.75052wk High1.34P/B1.83BFloat Cap22.36052wk Low--Dividend TTM67.69MShs Float77.400Historical High--Div YieldTTM2.64%Amplitude1.500Historical Low27.303Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Health care stocks were steady pre-bell Friday as the Health Care Select Sector SPDR Fund (XLV) was recently inactive and the iShares Biotechnology ETF (IBB) was down a slight 0.1%. Doximity (DOCS) ra
Express News | Integra Lifesciences- Accelerated Share Repurchase Agreement With Morgan Stanley to Repurchase $50 Mln of Co’s Outstanding Shares of Common Stock
Express News | Integra Lifesciences Holdings- on May 16, Entered Accelerated Share Repurchase Agreement With Morgan Stanley & Co
Integra LifeSciences: Expansion, Audits, and Share Repurchase Plan
Express News | Integra Lifesciences Holdings: Planning $50 Mln Share Repurchase as a Part of Previous Approval by Board
Integra LifeSciences to Present at the 2024 Bank of America Healthcare Conference
PRINCETON, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will
Comments
EPS growth doesn't align with share price, indicating it may not reflect business performance or growth expectations may have been high. Integra LifeSciences Holdings' performance led to a 3% annual loss for shareholders over five years. Investors should note 3 warning signs.
While Shareholders of Integra LifeSciences Holdings (NASDAQ:IART) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually GrownInsider transactions suggest a positive outlook for Integra LifeSciences Holdings, with insiders net buying the stock. The level of insider ownership indicates a reasonable degree of alignment with shareholder interests.
1
Integra LifeSciences Holdings trades at a low price, suggesting a buying opportunity. Higher cash flow is expected, potentially boosting share valuation. The positive outlook seems not fully factored into the share price, indicating it's not too late to buy IART.
Analysts insist that Integra LifeSciences' robust future growth justifies its high P/E, negating any expectations of a significant share price drop due to low odds of earnings deterioration.
The Acclarent acquisition provides Integra LifeSciences the chance to scale and seize leadership in the ENT device segment, enriching its innovative portfolio and providing shareholder value. In tandem with Integra's neurosurgery segment, it signifies a strategic move that will enhance innovation across ENT and other CSS technologies.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
